Using retinal markers to predict disease progression in neuroinflammatory diseases
Official title: Retinal Markers in Neuroinflammatory Diseases: a Prospective Observational Study
Run by University Hospital, Basel, Switzerland · NCT06369766 · Data updated 2026-11-12
This study is testing if eye exams can help predict how Multiple Sclerosis and other neuroinflammatory diseases will progress in patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 1 site (Basel) |
| Status | Recruiting |
| Started | January 31, 2024 |
| Main results expected | December 2028 |
| Study ends | February 2029 |
| Registry record updated | May 23, 2025 |
| Trial ID | NCT06369766 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 years old diagnosed with Multiple Sclerosis or other neuroinflammatory diseases.
✕Probably not a fit
Patients with significant ocular pathology or those unable to undergo Optical Coherence Tomography (OCT) may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the predictive value of retinal markers in patients with Multiple Sclerosis and other neuroinflammatory diseases, as well as healthy controls. Participants will undergo non-invasive retinal examinations and complete a questionnaire to assess various retinal measures. The focus is on identifying neuroaxonal loss and neuroinflammation in the retina, which may indicate progression independent of relapse activity (PIRA). The study seeks to improve early identification of patients at risk for PIRA, which is crucial for effective management of Multiple Sclerosis.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection of disease progression in patients with neuroinflammatory diseases, allowing for better therapeutic decisions.
How similar studies have gone: While the use of retinal markers in this context is promising, the specific predictive value for PIRA in neuroinflammatory diseases is still being explored and may represent a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. All groups: * Age \>18 years old 2. Patients with Multiple Sclerosis: * Diagnosis of Multiple Sclerosis, according to the last revisions of the McDonald Criteria (2017) 3. Patients with other neuroinflammatory diseases: * Diagnosis of Neuromyelitis optica spectrum disorder or Myelin oligodendrocyte glycoprotein antibody disease or other neuroinflammatory disorders other than Multiple Sclerosis Exclusion Criteria: 1. All groups: * Inability to undergo Optical Coherence Tomography (OCT) and/or retinal vessel imaging (e.g. severe nystagmus that prevents eye fixation on both eyes) * Presence of any ocular pathology that may interfere with the validity of the OCT/retinal vessel analysis (cataracts, glaucoma, history of refractive defects \>6 D etc.). * Pregnancy and Lactation 2. Healthy Controls * History of other neurological conditions: participants with a history of other significant neurological conditions that might interfere with the assessment or interpretation of the signs and symptoms will be excluded (e.g. confirmed Stroke, Acute disseminated encephalomyelitis, Chronic inflammatory Demyelinating Disease, Polyneuropathy, etc.)
Where it's running
-
University Hospital Basel, Department of Neurology
Basel, Switzerland Recruiting
Study contacts
- Principal investigator: Athina Papadopoulou, PD Dr. med. — University Hospital Basel, Department of Neurology
- Study coordinator: Athina Papadopoulou, PD Dr. med.
- Email: Athina.Papadopoulou@usb.ch
- Phone: +41 61 32 85704
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treadmill-based virtual reality walking training for MS patients
This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.
-
Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS
This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.
-
REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care
This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.
-
Tolebrutinib in real-world MS care for patients treated by clinicians
This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.
-
Pilates via live video vs. prerecorded videos for people with multiple sclerosis
This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.
-
Cooling During Inpatient Rehab for People with MS
This trial tests whether wearing a cooling vest during intensive training can reduce fatigue and improve walking, strength, balance, and cognition in people with multiple sclerosis during a 3-week inpatient rehab stay.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.